Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 ( HER2 ) Tyrosine Kinase Mutations in Lung Adenocarcinomas

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene

Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2

Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302

Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer

Slamon, D. J., Godolphin, W. J., Jones, L. A., Holt, J. A., Wong, S., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J. A., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,817

HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target

Grávalos, C., & Jimeno, A. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn169 · Cited by 1,205

A Hierarchical Network of Interreceptor Interactions Determines Signal Transduction by Neu Differentiation Factor/Neuregulin and Epidermal Growth Factor

Tzahar, E., Waterman, H., Chen, X., Levkowitz, G., Karunagaran, D., Lavi, S., Ratzkin, B. J., & Yarden, Y. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.10.5276 · Cited by 1,039

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

Gazdar, A. F. (2009) · Oncogene · doi:10.1038/onc.2009.198 · Cited by 991

Intragenic ERBB2 kinase mutations in tumours

Stephens, P., Hunter, C., Bignell, G., Edkins, S., Davies, H., Teague, J., Stevens, C., O'Meara, S., Smith, R., Parker, A., et al. (2004) · Nature · doi:10.1038/431525b · Cited by 802

Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions.

Pinkas‐Kramarski, R., Soussan, L., Waterman, H., Levkowitz, G., Alroy, I., Klapper, L. N., Lavi, S., Seger, R., Ratzkin, B. J., Sela, M., et al. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00603.x · Cited by 770

PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib

Engelman, J. A., Zejnullahu, K., Gale, C.-M., Lifshits, E., Gonzales, A. J., Shimamura, T., Zhao, F., Vincent, P. W., Naumov, G. N., Bradner, J. E., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1885 · Cited by 730

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Planchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., Mok, T. S., Reck, M., Van Schil, P. E., Hellmann, M. D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy275 · Cited by 2,274

Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

Kris, M. G., Johnson, B. E., Berry, L. D., Kwiatkowski, D. J., Iafrate, A. J., Wistuba, I. I., Varella-Garcia, M., Franklin, W. A., Aronson, S. L., Su, P.-F., et al. (2014) · JAMA · doi:10.1001/jama.2014.3741 · Cited by 1,724

The ErbB/HER family of protein-tyrosine kinases and cancer

Roskoski, R. J. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2013.11.002 · Cited by 1,408

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology

Lindeman, N. I., Cagle, P. T., Beasley, M. B., Chitale, D. A., Dacic, S., Giaccone, G., Jenkins, R. B., Kwiatkowski, D. J., Saldivar, J.-S., Squire, J., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318290868f · Cited by 1,280

Trastuzumab Deruxtecan in HER2 -Mutant Non–Small-Cell Lung Cancer

Li, B. T., Smit, E. F., Goto, Y., Nakagawa, K., Udagawa, H., Mazières, J., Nagasaka, M., Bazhenova, L. A., Saltos, A. N., Felip, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2112431 · Cited by 1,068

Understanding and targeting resistance mechanisms in NSCLC

Rotow, J. K., & Bivona, T. G. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.84 · Cited by 997

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology

Lindeman, N. I., Cagle, P. T., Aisner, D. L., Arcila, M. E., Beasley, M. B., Bernicker, E., Colasacco, C., Đačić, S., Hirsch, F. R., Kerr, K. M., et al. (2018) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2017-0388-cp · Cited by 975

Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives

Mazières, J., Peters, S., Lepage, B., Cortot, A. B., Barlesi, F., Beau-Faller, M., Besse, B., Blons, H., Mansuet-Lupo, A., Urban, T., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.6095 · Cited by 668

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors

Lindeman, N. I., Cagle, P. T., Aisner, D. L., Arcila, M. E., Beasley, M. B., Bernicker, E., Colasacco, C., Đačić, S., Hirsch, F. R., Kerr, K. M., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.12.001 · Cited by 669

Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS -Mutant Cancers

Dogan, S., Shen, R., Ang, D. C., Johnson, M. L., D'Angelo, S. P., Paik, P. K., Brzostowski, E. B., Riely, G. J., Kris, M. G., Zakowski, M. F., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3265 · Cited by 639

Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping

Paik, P. K., Drilon, A. E. D. C., Fan, P., Yu, H. A., Rekhtman, N., Ginsberg, M. S., Borsu, L. A., Schultz, N. D., Berger, M. F., Rudin, C. M., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1467 · Cited by 583

Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives

Имянитов, Е. Н., Iyevleva, A. G., & Levchenko, E. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103194 · Cited by 538

EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics

Arcila, M. E., Nafa, K., Chaft, J. E., Rekhtman, N., Lau, C., Reva, B. A., Zakowski, M. F., Kris, M. G., & Ladanyi, M. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0620 · Cited by 473

Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

Robichaux, J. P., Elamin, Y. Y., Tan, Z., Carter, B. W., Zhang, S., Liu, S., Li, S., Chen, T., Poteete, A., Estrada-Bernal, A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0007-9 · Cited by 468

Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas

Drilon, A. E. D. C., Wang, L., Hasanovic, A., Suehara, Y., Lipson, D., Stephens, P. J., Ross, J. S., Miller, V. A., Ginsberg, M. S., Zakowski, M. F., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0035 · Cited by 467

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors

Lindeman, N. I., Cagle, P. T., Beasley, M. B., Chitale, D. A., Đačić, S., Giaccone, G., Jenkins, R. B., Kwiatkowski, D. J., Saldivar, J., Squire, J. A., et al. (2013) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2013.03.001 · Cited by 461

Targeted Therapy and Checkpoint Immunotherapy in Lung Cancer

Ruiz‐Cordero, R., & Devine, W. P. (2020) · Surgical pathology clinics · doi:10.1016/j.path.2019.11.002 · Cited by 463

ErbB Receptors and Cancer

Wang, Z. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7219-7_1 · Cited by 448

Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: the lung cancer mutation consortium experience

Sholl, L. M., Aisner, D. L., Varella-Garcia, M., Berry, L. D., Dias-Santagata, D., Wistuba, I. I., Chen, H., Fujimoto, J., Kugler, K., Franklin, W. A., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000516 · Cited by 430

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology

Lindeman, N. I., Cagle, P. T., Beasley, M. B., Chitale, D. A., Đačić, S., Giaccone, G., Jenkins, R. B., Kwiatkowski, D. J., Saldivar, J., Squire, J. A., et al. (2013) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2012-0720-oa · Cited by 426

Genomic alterations in lung adenocarcinoma

Devarakonda, S. H. K., Morgensztern, D., & Govindan, R. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00077-7 · Cited by 423

Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer

Vyse, S., & Huang, P. H. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0038-9 · Cited by 390

Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions

Oxnard, G. R., Lo, P. C., Nishino, M., Dahlberg, S. E., Lindeman, N. I., Butaney, M., Jackman, D. M., Johnson, B. E., & Jänne, P. A. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182779d18 · Cited by 360

Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer

Meric‐Bernstam, F., Johnson, A. M., Dumbrava, E. E. I., Raghav, K. P. S., Balaji, K., Bhatt, M., Murthy, R. K., Rodon, J. A., & Piha-Paul, S. A. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2275 · Cited by 348

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors

Lindeman, N. I., Cagle, P. T., Aisner, D. L., Arcila, M. E., Beasley, M. B., Bernicker, E., Colasacco, C., Đačić, S., Hirsch, F. R., Kerr, K. M., et al. (2018) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2017.11.004 · Cited by 351

Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors

Kris, M. G., Camidge, D. R., Giaccone, G., Hida, T., Li, B. T., O'Connell, J., Taylor, I., Zhang, H., Arcila, M. E., Goldberg, Z., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv186 · Cited by 334

Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network

Beau-Faller, M., Prim, N., Ruppert, A.-M., Nanni-Metéllus, I., Lacave, R., Lacroix, L., Escande, F., Lizard, S., Pretet, J.-L., Rouquette, I., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt418 · Cited by 324

Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort

Mazières, J., Barlési, F., Filleron, T., Besse, B., Monnet, I., Beau‐Faller, M., Peters, S., Dansin, É., Früh, M., Pless, M., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv573 · Cited by 326

Lung cancer in patients who have never smoked — an emerging disease

LoPiccolo, J., Gusev, A., Christiani, D. C., & Janne, P. A. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00844-0 · Cited by 320

HER2 amplification and HER2 mutation are distinct molecular targets in lung cancers

Li, B. T., Ross, D. S., Aisner, D. L., Chaft, J. E., Hsu, M., Kako, S. L., Kris, M. G., Varella-Garcia, M., & Arcila, M. E. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.10.025 · Cited by 286

Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non–Small-Cell Lung Cancer

Sacher, A. G., Dahlberg, S. E., Heng, J. C., Mach, S. L., Janne, P. A., & Oxnard, G. R. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4482 · Cited by 261

PTEN and PI3K/AKT in Non-Small-Cell Lung Cancer

Pérez-Ramírez, C., Cañadas‐Garre, M., Molina‐Vila, M. Á., Faus-Dáder, M. J., & Calleja‐Hernández, M. Á. (2015) · Pharmacogenomics · doi:10.2217/pgs.15.122 · Cited by 246

Drug resistance to targeted therapeutic strategies in non-small cell lung cancer

Liu, W., Du, Y., Wen, R. M., Yang, M., & Xu, J. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107438 · Cited by 223

HER2 aberrations in cancer: Implications for therapy

Yan, M., Parker, B. A., Schwab, R. B., & Kurzrock, R. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.02.008 · Cited by 212

HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium

Pillai, R. N., Behera, M., Berry, L. D., Rossi, M. R., Kris, M. G., Johnson, B. E., Bunn, P. A., Ramalingam, S. S., & Khuri, F. R. (2017) · Cancer · doi:10.1002/cncr.30869 · Cited by 216

HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib

Wang, Y., Jiang, T., Qin, Z., Jiang, J., Wang, Q., Yang, S., Rivard, C. J., Gao, G., Ng, T. L., Tu, M. M., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy542 · Cited by 210

Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations

Riudavets, M., Sullivan, I., Abdayem, P., & Planchard, D. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100260 · Cited by 202

EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment

Friedlaender, A., Subbiah, V., Russo, A., Banna, G. L., Malapelle, U., Rolfo, C. D., & Addeo, A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00558-1 · Cited by 210

Identification of KIF5B-RET and GOPC-ROS1 Fusions in Lung Adenocarcinomas through a Comprehensive mRNA-Based Screen for Tyrosine Kinase Fusions

Suehara, Y., Arcila, M. E., Wang, L., Hasanovic, A., Ang, D. C., Ito, T., Kimura, Y., Drilon, A. E. D. C., Guha, U., Rusch, V. W., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0838 · Cited by 181

Identifying the Appropriate FISH Criteria for Defining MET Copy Number–Driven Lung Adenocarcinoma through Oncogene Overlap Analysis

Noonan, S. A., Berry, L. D., Lu, X. J. D., Gao, D., Barón, A. E., Chesnut, P., Sheren, J. E., Aisner, D. L., Merrick, D., Doebele, R. C., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.04.033 · Cited by 179

Activating HER2 mutations as emerging targets in multiple solid cancers

Connell, C. M., & Doherty, G. J. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000279 · Cited by 169

Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP)

Dziadziuszko, R., Smit, E. F., Dafni, U. G., Wolf, J., Wasąg, B., Biernat, W., Finn, S. P., Kammler, R., Tsourti, Z., Rabaglio, M., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.02.017 · Cited by 162

Molecular biomarkers for lung adenocarcinoma

Calvayrac, O., Pradines, A., Tostivint, E. P., Mazières, J., & Guibert, N. M. (2017) · European Respiratory Journal · doi:10.1183/13993003.01734-2016 · Cited by 160

Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms

Yamaoka, T., Ohba, M., & Ohmori, T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112420 · Cited by 156

Uncommon EGFR mutations in advanced non-small cell lung cancer

O'Kane, G. M., Bradbury, P. A., Feld, R. D., Leighl, N. B., Liu, G., Pisters, K.-M., Kamel‐Reid, S., Tsao, M., & Shepherd, F. A. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.04.016 · Cited by 153

Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma

Lamberti, G., Andrini, E., Sisi, M., Rizzo, A., Parisi, C., Federico, A. D., Gelsomino, F., & Ardizzoni, A. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103119 · Cited by 147

Molecularly Targeted Therapies in Non–Small-Cell Lung Cancer Annual Update 2014

Morgensztern, D., Campo, M. J., Dahlberg, S. E., Doebele, R. C., Garon, E. B., Gerber, D. E., Goldberg, S. B., Hammerman, P. S., Heist, R. S., Hensing, T. A., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000405 · Cited by 138

Relapsed Classic E-Cadherin ( CDH1 )–Mutated Invasive Lobular Breast Cancer Shows a High Frequency of HER2 ( ERBB2 ) Gene Mutations

Ross, J. S., Wang, K., Sheehan, C. E., Boguniewicz, A. B., Otto, G., Downing, S. R., Sun, J., He, J., Curran, J. A., Ali, S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0295 · Cited by 135

Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors

Kosaka, T., Tanizaki, J., Paranal, R. M., Endoh, H., Lydon, C., Capelletti, M., Repellin, C. E., Choi, J., Ogino, A., Calles, A., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3404 · Cited by 131

Genomic alterations of ERBB receptors in cancer: clinical implications

Mishra, R., Hanker, A. B., & Garrett, J. T. (2017) · Oncotarget · doi:10.18632/oncotarget.22825 · Cited by 132

The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal

Gristina, V., Malapelle, U., Galvano, A., Pisapia, P., Pepe, F., Rolfo, C. D., Tortorici, S., Bazan, V., Troncone, G., & Russo, A. D. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.101994 · Cited by 124

Epidermal Growth Factor Receptor Inhibition in Lung Cancer: Status 2012

Hirsch, F. R., Janne, P. A., Eberhardt, W., Cappuzzo, F., Thatcher, N., Pirker, R., Choy, H., Kim, E. S., Paz-Ares, L. G., Gandara, D. R., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31827ed0ff · Cited by 122

Consensus for HER2 alterations testing in non-small-cell lung cancer

Ren, S., Wang, J., Ying, J., Mitsudomi, T., Lee, D., Wang, Z., Chu, Q., Mack, P. C., Cheng, Y., Duan, J., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100395 · Cited by 127

Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations

König, D., Prince, S. S., & Rothschild, S. I. (2021) · Cancers · doi:10.3390/cancers13040804 · Cited by 119

Targeted Therapies in Non-Small Cell Lung Cancer—Beyond EGFR and ALK

Rothschild, S. I. (2015) · Cancers · doi:10.3390/cancers7020816 · Cited by 117

The frequency and clinical impact of HER2 alterations in lung adenocarcinoma

Kim, E., Kim, K., Lee, C. Y., & Shim, H. S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0171280 · Cited by 113

Comprehensive Characterization of Oncogenic Drivers in Asian Lung Adenocarcinoma

Li, S., Choi, Y., Gong, Z., Liu, X., Lira, M. E., Kan, Z., Oh, E., Wang, J., Ting, J. C., Ye, X. S., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.08.142 · Cited by 114

Targeting HER2 Alterations in Non–Small-Cell Lung Cancer: A Comprehensive Review

Zhao, J., & Xia, Y. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00333 · Cited by 108

Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes

Chang, J. C., Offin, M. D., Falcon, C. J., Brown, D. N., Houck-Loomis, B. R., Meng, F., Rudneva, V. A., Won, H. H., Amir, S., Montecalvo, J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0423 · Cited by 107

Targeted next‐generation sequencing using fine‐needle aspirates from adenocarcinomas of the lung

Karnes, H. E., Duncavage, E. J., & Bernadt, C. T. (2013) · Cancer Cytopathology · doi:10.1002/cncy.21361 · Cited by 106

Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer

Halliday, P. R., Blakely, C. M., & Bivona, T. G. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0770-x · Cited by 111

Targeting EGFR Exon 20 Insertions in Non–Small Cell Lung Cancer: Recent Advances and Clinical Updates

Meador, C. B., Sequist, L. V. D., & Piotrowska, Z. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0226 · Cited by 104

Emerging evidence and treatment paradigm of non-small cell lung cancer

Liu, S. M., Zheng, M.-M., Pan, Y., Liu, S. M., Li, Y., & Wu, Y.-L. L. C. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01436-2 · Cited by 112

Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials

Suh, J. H., Johnson, A., Albacker, L. A., Wang, K., Chmielecki, J., Frampton, G. M., Gay, L. M., Elvin, J. A., Vergilio, J., Ali, S. M., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0030 · Cited by 104

Targeting HER2 in the treatment of non-small cell lung cancer

Mar, N., Vredenburgh, J. J., & Wasser, J. S. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2014.12.018 · Cited by 102

Emergence of ERBB2 Mutation as a Biomarker and an Actionable Target in Solid Cancers

Subramanian, J., Katta, A., Masood, A., Vudem, D. R., & Kancha, R. K. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0845 · Cited by 105

Tyrosine Kinase Receptors in Oncology

Esteban-Villarrubia, J., Castillo, J. J. S., Pozas, J., Román, M. S., Orejana, I., Torres-Jiménez, J., Carrato, A., Alonso‐Gordoa, T., & Molina‐Cerrillo, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228529 · Cited by 104

Oncogenic Alterations in ERBB2/HER2 Represent Potential Therapeutic Targets Across Tumors From Diverse Anatomic Sites of Origin

Chmielecki, J., Ross, J. S., Wang, K., Frampton, G. M., Palmer, G. A., Ali, S. M., Palma, N. A., Morosini, D., Miller, V. A., Yelensky, R., et al. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0234 · Cited by 101

Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives

Ferrara, M. G., Noia, V. D., D’Argento, E., Vita, E., Damiano, P., Cannella, A., Ribelli, M., Pilotto, S., Milella, M., Tortora, G., et al. (2020) · Cancers · doi:10.3390/cancers12051196 · Cited by 101

HER2 status in lung adenocarcinoma: A comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations

Yoshizawa, A., Sumiyoshi, S., Sonobe, M., Kobayashi, M., Uehara, T., Fujimoto, M., Tsuruyama, T., Date, H., & Haga, H. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.06.007 · Cited by 94

The Prognostic Impact of KRAS, Its Codon and Amino Acid Specific Mutations, on Survival in Resected Stage I Lung Adenocarcinoma

Izar, B., Zhou, H., Heist, R. S., Azzoli, C. G., Muzikansky, A., Scribner, E. E. F., Bernardo, L. A., Dias-Santagata, D. C., Iafrate, A. J., & Lanuti, M. D. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000266 · Cited by 93

ERBB2 -Mutated Metastatic Non–Small Cell Lung Cancer: Response and Resistance to Targeted Therapies

Chuang, J. C., Stehr, H., Liang, Y., Das, M. S., Huang, J. Q., Diehn, M., Wakelee, H. A., & Neal, J. W. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.01.023 · Cited by 91

Magnetic particle targeting for diagnosis and therapy of lung cancers

Saadat, M., Manshadi, M. K. D., Mohammadi, M., Zare, M. J., Zarei, M., Kamali, R., & Sanati‐Nezhad, A. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.09.017 · Cited by 91

Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma

Grève, J. D., Morán, T., Graas, M.-P., Galdermans, D., Vuylsteke, P., Canon, J.-L. R., Schallier, D. C. C., Decoster, L., Teugels, E., Massey, D., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.01.013 · Cited by 91

ErbB2 Pathway Activation upon Smad4 Loss Promotes Lung Tumor Growth and Metastasis

Liu, J., Cho, S.-N., Akkanti, B. H., Jin, N., Mao, J., Long, W., Chen, T., Zhang, Y., Tang, X., Wistub, I. I., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.02.014 · Cited by 90

Endogenous CD4+ T Cells Recognize Neoantigens in Lung Cancer Patients, Including Recurrent Oncogenic KRAS and ERBB2 ( Her2 ) Driver Mutations

Veatch, J. R., Jesernig, B. L., Kargl, J., Fitzgibbon, M., Lee, S. M., Baik, C., Martins, R., Houghton, A. M., & Riddell, S. R. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0402 · Cited by 89

Prognostic and predictive biomarkers in lung cancer. A review

Thunnissen, E., der Oord, K. V., & den Bakker, M. (2014) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-014-1535-4 · Cited by 92

Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment

Herter-Sprie, G. S., Greulich, H. E., & Wong, K. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00086 · Cited by 88

Frequency and outcomes of brain metastases in patients with HER2‐mutant lung cancers

Offin, M. D., Feldman, D., Ni, A., Myers, M. L., Lai, W. V., Pentsova, E. I., Boire, A. A., Daras, M., Jordan, E., Solit, D. B., et al. (2019) · Cancer · doi:10.1002/cncr.32461 · Cited by 89

Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer

Nahta, R. (2012) · ISRN Oncology · doi:10.5402/2012/428062 · Cited by 93

Application of the CRISPR/Cas9 System to Drug Resistance in Breast Cancer

Chen, Y., & Zhang, Y. (2018) · Advanced Science · doi:10.1002/advs.201700964 · Cited by 91

Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation–Positive Advanced NSCLC: Findings From a Global Named Patient Use Program

Peters, S., Fontecedro, A. C., Nechushtan, H., Shih, J., Liao, W., Gautschi, O. P., Spataro, V. J., Unk, M., Yang, J. C., Lorence, R. M., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.07.093 · Cited by 85

The force of HER2 – A druggable target in NSCLC?

Jebbink, M., Langen, A. J. D., Boelens, M. C., Monkhorst, K., & Smit, E. F. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.101996 · Cited by 85

Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non–Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial

Mazières, J., Lafitte, C., Ricordel, C., Greillier, L., Negre, E., Zalcman, G., Domblides, C., Madelaine, J., Bennouna, J., Mascaux, C., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01455 · Cited by 84

Targeted therapies in development for non-small cell lung cancer

Dy, G. K., & Reungwetwattana, T. (2013) · Journal of Carcinogenesis · doi:10.4103/1477-3163.123972 · Cited by 80

Trastuzumab emtansine for patients with non–small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations

Iwama, E., Zenke, Y., Sugawara, S., Daga, H., Morise, M., Yanagitani, N., Sakamoto, T., Murakami, H., Kishimoto, J., Matsumoto, S., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.11.021 · Cited by 81

Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study

Lai, W. V., Lebas, L., Barnes, T. A., Milia, J., Ni, A., Gautschi, O. P., Peters, S., Ferrara, R., Plodkowski, A. J., Kavanagh, J., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.11.030 · Cited by 79

NSCLC and HER2: between lights and shadows

Ricciardi, G. R. R., Russo, A., Franchina, T., Ferraro, G., Zanghì, M., Picone, A., Scimone, A., & Adamo, V. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000379 · Cited by 78

Targeted therapy in NSCLC driven by HER2 insertions.

Peters, S., & Zimmermann, S. (2014) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2014.02.06 · Cited by 77

Antitumor effect of afatinib, as a human epidermal growth factor receptor 2‐targeted therapy, in lung cancers harboring HER 2 oncogene alterations

Suzawa, K., Toyooka, S., Sakaguchi, M., Morita, M., Yamamoto, H., Tomida, S., Ohtsuka, T., Watanabe, M., Hashida, S., Maki, Y., et al. (2015) · Cancer Science · doi:10.1111/cas.12845 · Cited by 77

HER2 in Non-Small Cell Lung Cancer: A Review of Emerging Therapies

Uy, N. F., Merkhofer, C. M., & Baik, C. S. (2022) · Cancers · doi:10.3390/cancers14174155 · Cited by 82

Mutations in the Kinase Domain of the HER2/ERBB2 Gene Identified in a Wide Variety of Human Cancers

Wen, W., Chen, W., Xiao, N., Bender, R. P., Ghazalpour, A., Tan, Z., Swensen, J. J., Millis, S. Z., Basu, G. D., Gatalica, Z., et al. (2015) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2015.04.003 · Cited by 76

Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer

Zuo, W., Jiang, Y., Wang, Y.-J., Xu, X., Hu, X. Y., Liu, G., Wu, J., Di, G., Yu, K., & Shao, Z.-M. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3036 · Cited by 76

HER2 gene mutations in non-small cell lung carcinomas: Concurrence with her2 gene amplification and her2 protein expression and phosphorylation

Suzuki, M., Shiraishi, K., Yoshida, A., Shimada, Y., Suzuki, K., Asamura, H., Furuta, K., Kohno, T., & Tsuta, K. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.10.014 · Cited by 75

Current Approaches in NSCLC Targeting K-RAS and EGFR

Aran, V., & Omerović, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225701 · Cited by 74

Targeting HER2 alterations in non-small cell lung cancer: Therapeutic breakthrough and challenges

Yu, Y., Yang, Y., Li, H., & Fan, Y. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102520 · Cited by 75

Comprehensive pancancer genomic analysis reveals (RTK)-RAS-RAF-MEK as a key dysregulated pathway in cancer: Its clinical implications

Imperial, R. J. L., Toor, O. M., Hussain, A., Subramanian, J., & Masood, A. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.016 · Cited by 74

HER2 and lung cancer

Landi, L. M., & Cappuzzo, F. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2013.846830 · Cited by 73

Profiling of Oncogenic Driver Events in Lung Adenocarcinoma Revealed MET Mutation as Independent Prognostic Factor

Yeung, S. F., TONG, J. H. M., Law, P. P. Y., Chung, L. Y., Lung, R. W. M., Tong, C. Y., Chow, C., Chan, A. W. H., Wan, I. Y. P., Mok, T. S. K., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000620 · Cited by 70

Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers

Wang, Y., Zhang, S., Wu, F., Zhao, J., Li, X., Zhao, C., Ren, S., & Zhou, C. (2018) · BMC Cancer · doi:10.1186/s12885-018-4277-x · Cited by 70

Molecular and clinicopathologic characteristics of HER2-mutant lung adenocarcinoma (ADC).

Arcila, M. E., Chaft, J. E., Nafa, K., Kris, M. G., Zakowski, M. F., & Ladanyi, M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.10596 · Cited by 2

Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: Mutations are mainly present in adenocarcinomas with bronchioloalveolar features

Buttitta, F., Barassi, F., Fresu, G., Felicioni, L., Chella, A., Paolizzi, D., Lattanzio, G., Salvatore, S., Camplese, P. P., Rosini, S., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.22143 · Cited by 180

Lung Adenocarcinomas with HER2-Activating Mutations Are Associated with Distinct Clinical Features and HER2/EGFR Copy Number Gains

Li, C., Sun, Y., Fang, R., Han, X., Luo, X., Wang, R., Pan, Y., Hu, H., Zhang, Y., Pao, W. J., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318234f0a2 · Cited by 96

Somatic Mutations of the HER2 Kinase Domain in Lung Adenocarcinomas

Shigematsu, H., Takahashi, T., Nomura, M., Majmudar, K., Suzuki, M., Lee, H., Wistuba, I. I., Fong, K. M., Toyooka, S., Shimizu, N., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4235 · Cited by 678

HER-2 mutations in Chinese lung adenocarcinoma patients with negative EGFR mutations.

Zhou, C., Li, X., Zhao, C., Su, C., & Ren, S. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.e12649